UY33366A - FIBRONECTINA TIPO III A LA DÉCIMA (10Fn3) DE UNIÓN A SEROALBÚMINA Y MOLÉCULAS DE FUSIÓN QUE LAS COMPRENDE - Google Patents

FIBRONECTINA TIPO III A LA DÉCIMA (10Fn3) DE UNIÓN A SEROALBÚMINA Y MOLÉCULAS DE FUSIÓN QUE LAS COMPRENDE

Info

Publication number
UY33366A
UY33366A UY0001033366A UY33366A UY33366A UY 33366 A UY33366 A UY 33366A UY 0001033366 A UY0001033366 A UY 0001033366A UY 33366 A UY33366 A UY 33366A UY 33366 A UY33366 A UY 33366A
Authority
UY
Uruguay
Prior art keywords
serioalbumin
fibronectine
union
fusion molecules
understand
Prior art date
Application number
UY0001033366A
Other languages
English (en)
Inventor
Camphausen Ray
Sharon T Cload
Tracy S Mitchell
Michael L Gosselin
Fabrizio David
Joanna F Swaim
Furfine Eric
Paul E Morin
Mukherjee Ranjan
Simeon I Taylor
Original Assignee
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Publication of UY33366A publication Critical patent/UY33366A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)

Abstract

La presente invención se refiere a una proteína tipo anticuerpo que se basa en el dominio de fibroctina tipo III a la déctima (10Fn3) que se une a seroalbúmina. La invención también se refiere a moléculas de fusión que comprenden una 10Fn3 de unión a seroalbúmina ligada a una proteína heteróloga para usar en aplicaciones terapéuticas y de diagnóstico.
UY0001033366A 2010-05-03 2011-05-03 FIBRONECTINA TIPO III A LA DÉCIMA (10Fn3) DE UNIÓN A SEROALBÚMINA Y MOLÉCULAS DE FUSIÓN QUE LAS COMPRENDE UY33366A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33067210P 2010-05-03 2010-05-03

Publications (1)

Publication Number Publication Date
UY33366A true UY33366A (es) 2011-10-31

Family

ID=44628186

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033366A UY33366A (es) 2010-05-03 2011-05-03 FIBRONECTINA TIPO III A LA DÉCIMA (10Fn3) DE UNIÓN A SEROALBÚMINA Y MOLÉCULAS DE FUSIÓN QUE LAS COMPRENDE

Country Status (21)

Country Link
US (4) US8969289B2 (es)
EP (1) EP2566888A2 (es)
JP (3) JP5876872B2 (es)
KR (1) KR101854931B1 (es)
CN (2) CN107698682A (es)
AR (1) AR081459A1 (es)
AU (1) AU2011248273B2 (es)
BR (1) BR112012028162A2 (es)
CA (1) CA2798510A1 (es)
CL (1) CL2012003077A1 (es)
CO (1) CO6630173A2 (es)
EA (1) EA029334B1 (es)
IL (1) IL222832A0 (es)
MX (2) MX2012012800A (es)
PE (1) PE20130593A1 (es)
SG (2) SG185091A1 (es)
TN (1) TN2012000518A1 (es)
TW (1) TW201138808A (es)
UY (1) UY33366A (es)
WO (1) WO2011140086A2 (es)
ZA (1) ZA201209091B (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060129246A (ko) 2003-12-05 2006-12-15 컴파운드 쎄라퓨틱스, 인크. 타입 2 혈관 내피 성장 인자 수용체의 억제제
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
US8178495B2 (en) * 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
AU2008232937B2 (en) 2007-03-30 2012-09-27 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
KR20100128291A (ko) 2008-02-14 2010-12-07 브리스톨-마이어스 스큅 컴퍼니 Ｅｇｆｒ에 결합하는 조작된 단백질을 기초로 하는 표적화된 치료제
EP2799448A1 (en) 2008-05-22 2014-11-05 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
ES2573108T3 (es) 2010-05-26 2016-06-06 Bristol-Myers Squibb Company Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada
US9139629B2 (en) * 2010-06-05 2015-09-22 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
US9475850B2 (en) * 2010-06-05 2016-10-25 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
WO2012116264A1 (en) 2011-02-24 2012-08-30 The Trustees Of The University Of Pennsylvania Biomarkers for seizures
WO2012122464A1 (en) * 2011-03-10 2012-09-13 New York University Methods and compositions for modulating tnf/tnfr signaling
EP3144320B9 (en) 2011-04-13 2018-08-22 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
US9347058B2 (en) 2011-05-17 2016-05-24 Bristol-Myers Squibb Company Methods for the selection of binding proteins
EP2709669A1 (en) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
JP6006309B2 (ja) * 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニーＡｍｙｌｉｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｌｌｃ 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
EP2773659A2 (en) 2011-10-31 2014-09-10 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
GB2501611B (en) 2012-02-21 2015-03-04 Cytonics Corp Alpha-2-macroglobulin compositions and therapeutic uses
US8933199B2 (en) 2012-09-13 2015-01-13 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
WO2014100913A1 (en) * 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
EP2951206A2 (en) 2013-02-01 2015-12-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
WO2014124017A1 (en) * 2013-02-06 2014-08-14 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
WO2014126884A1 (en) 2013-02-12 2014-08-21 Bristol-Myers Squibb Company High ph protein refolding methods
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
ES2708957T3 (es) 2013-03-14 2019-04-12 Regeneron Pharma Proteínas de fusión de apelina y usos de las mismas
CN103333255A (zh) * 2013-06-28 2013-10-02 复旦大学 一种长效hiv‐1膜融合抑制剂
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
CA2918074A1 (en) 2013-07-25 2015-01-29 Novartis Ag Cyclic polypeptides for the treatment of heart failure
CN103550790B (zh) * 2013-11-04 2016-01-27 上海交通大学医学院附属瑞金医院 骨膜蛋白抗体及其在药物制备中的应用
CA2931299C (en) 2013-11-20 2024-03-05 Regeneron Pharmaceuticals, Inc. Aplnr modulators and uses thereof
CN113150117A (zh) * 2014-03-20 2021-07-23 百时美施贵宝公司 新的结合血清白蛋白的纤连蛋白iii型结构域
CN113604543A (zh) * 2014-03-27 2021-11-05 豪夫迈·罗氏有限公司 用于诊断和治疗炎症性肠病的方法
JP6702962B2 (ja) 2014-10-24 2020-06-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改変ｆｇｆ−２１ポリペプチドおよびその使用
PE20170782A1 (es) 2014-11-21 2017-07-04 Bristol Myers Squibb Co Anticuerpos frente a cd73 y usos de los mismos
ES2941895T3 (es) 2014-11-25 2023-05-26 Bristol Myers Squibb Co Métodos y composiciones para radioetiquetado con 18F del dominio de fibronectina tipo (III)
BR112017010137A2 (pt) 2014-11-25 2018-02-06 Bristol-Myers Squibb Company polipeptídios fixadores de pd-l1 para imagem
CN104587457B (zh) * 2015-01-13 2017-03-22 广东海大畜牧兽医研究院有限公司 一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法
CU20170093A7 (es) 2015-01-23 2017-09-06 Novartis Ag Conjugados de ácidos grasos y apelina sintética con mayor vida media
US10849992B1 (en) * 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
JP6894846B2 (ja) * 2015-04-24 2021-06-30 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド Ｈｉｖ融合体を標的とするポリペプチド
AU2016274175B2 (en) * 2015-06-12 2021-02-18 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Methods and polypeptides for modulation of immunoresponse
WO2017024137A1 (en) * 2015-08-04 2017-02-09 New York University Progranulin (pgrn) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
EP3708580B1 (en) 2015-09-23 2023-11-01 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains
WO2017180988A2 (en) 2016-04-15 2017-10-19 Indiana University Research And Technology Corporation Fgf21 c-terminal peptide optimization
KR102397783B1 (ko) 2016-06-01 2022-05-12 브리스톨-마이어스 스큅 컴퍼니 Pd-l1 결합 폴리펩티드에 의한 pet 영상화
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
US10925932B2 (en) 2016-06-03 2021-02-23 Janssen Biotech, Inc. Serum albumin-binding fibronectin type III domains
CN106110325A (zh) * 2016-06-08 2016-11-16 上海朗安生物技术有限公司 一种新型 glp‑1 受体激动剂的制备方法及其在神经退行性疾病治疗领域的应用
CN107693775A (zh) * 2016-08-08 2018-02-16 中国人民解放军沈阳军区总医院 Creg蛋白用于预防或治疗体重超重、肥胖及其相关疾病的医药用途
US11096998B2 (en) * 2016-09-14 2021-08-24 Janssen Biotech, Inc. Chimeric antigen receptors comprising BCMA-specific fibronectin type III domains and uses thereof
WO2018165344A1 (en) * 2017-03-08 2018-09-13 The Regents Of The University Of Michigan Glypican-3 peptide reagents and methods
WO2018165933A1 (zh) * 2017-03-16 2018-09-20 深圳先进技术研究院 调节糖代谢的多肽及其用途
EP3626734A4 (en) * 2017-03-16 2020-12-02 Shenzhen Institutes of Advanced Technology POLYPEPTIDE FOR REGULATING ENERGY METABOLISM AND USES THEREOF
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
WO2019014360A1 (en) * 2017-07-11 2019-01-17 Alexion Pharmaceuticals, Inc. POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF
CN109957005B (zh) * 2017-12-22 2021-04-20 深圳先进技术研究院 一种代谢素多肽人工抗原及其制备方法、抗体以及应用
CN109957006B (zh) * 2017-12-22 2021-04-20 深圳先进技术研究院 一种代谢素多肽人工抗原以及抗体和应用
WO2019246004A1 (en) * 2018-06-18 2019-12-26 Anwita Biosciences, Inc. Cytokine fusion proteins and uses thereof
KR102273123B1 (ko) * 2018-10-24 2021-07-05 한국과학기술원 인간 혈장 알부민에 특이적으로 결합하는 신규한 폴리펩티드 및 이의 용도
CN110582515A (zh) * 2018-11-12 2019-12-17 天境生物科技(上海)有限公司 包含cd47抗体和细胞因子的融合蛋白
CN109821012A (zh) * 2019-04-08 2019-05-31 河南师范大学 一种用于治疗代谢疾病的药物组合物及其缓释微球制剂
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
CN111965356B (zh) * 2019-11-28 2023-09-08 上海荣盛生物药业股份有限公司 巯基还原组合物及荧光微球层析试纸和应用
CN113092772A (zh) * 2019-12-23 2021-07-09 首都医科大学附属北京世纪坛医院 尿液黏连蛋白亚组sa-2及其多肽片段在过敏性疾病中的应用
CN111521812B (zh) * 2019-12-25 2023-02-17 瑞博奥(广州)生物科技股份有限公司 视神经脊髓炎谱系疾病生物标记物组及其应用和蛋白芯片、试剂盒
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
CN112694526B (zh) * 2020-05-27 2023-01-20 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白
AU2021280623B9 (en) * 2020-05-27 2024-03-14 Sciwind Biosciences Co., Ltd. Interleukin 29 mutant protein
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
CN114075272B (zh) * 2020-08-10 2023-09-22 杭州俊丰生物工程有限公司 一种人神经调节蛋白4的制备方法
CN111983241B (zh) * 2020-09-04 2022-05-20 四川大学华西医院 诊断脑卒中认知障碍的蛋白标志物以及模型的训练方法
CN112321720A (zh) * 2020-11-05 2021-02-05 无锡和邦生物科技有限公司 一种艾塞那肽人血清白蛋白融合蛋白的纯化方法
CN114848795B (zh) * 2021-02-03 2023-04-14 四川大学 RORa蛋白及其激动剂在制备抗衰老药物中的应用
CN112870336B (zh) * 2021-02-24 2022-06-14 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白制剂
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
KR20240034235A (ko) * 2021-07-14 2024-03-13 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 대사 장애를 위한 융합 폴리펩타이드
WO2023057946A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
CN114288414A (zh) * 2021-12-07 2022-04-08 深圳先进技术研究院 一种跨血脑屏障的多肽及其衍生物和应用
CN114306630A (zh) * 2021-12-07 2022-04-12 深圳先进技术研究院 一种靶向脑瘤的多肽及其衍生物和应用
WO2023183932A2 (en) * 2022-03-25 2023-09-28 New York University Monobodies binding to intercellular adhesion molecule 2 (icam-2)
CN114432429A (zh) * 2022-04-12 2022-05-06 中国人民解放军军事科学院军事医学研究院 一种预防或治疗骨关节炎的活性分子及其应用
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
CN117645661A (zh) * 2022-09-02 2024-03-05 北京志道生物科技有限公司 一种聚乙二醇修饰的il-21衍生物及其应用
WO2024051796A1 (en) * 2022-09-09 2024-03-14 Wuxi Biologics (Shanghai) Co., Ltd. Albumin binding proteins, fusion proteins and uses thereof
CN115433776B (zh) * 2022-09-30 2023-12-22 中国医学科学院阜外医院 Ccn3在调控血管平滑肌细胞钙化中的应用
CN115724951B (zh) * 2022-11-15 2023-10-03 怡道生物科技(苏州)有限公司 与11型hpv结合的抗体或其抗原结合片段及其应用

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5770697A (en) 1986-11-04 1998-06-23 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US5641648A (en) 1986-11-04 1997-06-24 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US5367052A (en) 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
AU8498091A (en) 1990-08-02 1992-03-02 Regents Of The University Of Colorado, The Systematic polypeptide evolution by reverse translation
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5773574A (en) 1990-12-03 1998-06-30 The Scripps Research Institute Polypeptides for promoting cell attachment
US5235041A (en) 1990-12-28 1993-08-10 Protein Polymer Technologies, Inc. Purification of structurally ordered recombinant protein polymers
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5792742A (en) 1991-06-14 1998-08-11 New York University Fibrin-binding peptide fragments of fibronectin
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
EP0592562B1 (en) 1991-06-25 1999-01-07 Genetics Institute, Inc. Bmp-9 compositions
WO1993003172A1 (en) 1991-08-01 1993-02-18 University Research Corporation Systematic polypeptide evolution by reverse translation
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
WO1994017097A1 (en) 1993-01-19 1994-08-04 Regents Of The University Of Minnesota Synthetic fibronectin fragments as inhibitors of retroviral infections
PL310897A1 (en) 1993-03-29 1996-01-08 Univ Cincinnati Analogues of yy peptide and their application
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5559000A (en) 1995-01-18 1996-09-24 The Scripps Research Institute Encoded reaction cassette
DE19646372C1 (de) 1995-11-11 1997-06-19 Evotec Biosystems Gmbh Genotyp und Phänotyp koppelnde Verbindung
GB9618960D0 (en) 1996-09-11 1996-10-23 Medical Science Sys Inc Proteases
US5922676A (en) 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
EP0962527B1 (en) 1996-10-17 2004-08-04 Mitsubishi Chemical Corporation Molecule that homologizes genotype and phenotype and utilization thereof
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
EP1712623B1 (en) 1997-01-21 2011-10-19 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US5830434A (en) 1997-02-26 1998-11-03 Medical University Of South Carolina Foundation For Research Development Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
WO1998048837A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US6159722A (en) 1997-12-03 2000-12-12 Boehringer Mannheim Gmbh Chimeric serine proteases
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
EP1068356B8 (en) 1998-04-03 2007-01-03 Adnexus Therapeutics, Inc. Addressable protein arrays
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
EP1137941B2 (en) 1998-12-10 2013-09-11 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
MXPA01010891A (es) 1999-04-28 2002-11-07 Univ Texas Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf).
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
CA2377468C (en) 1999-07-27 2010-04-20 Phylos, Inc. Peptide acceptor ligation methods
WO2001072829A2 (en) 2000-03-31 2001-10-04 Institut Pasteur Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
EP1364009A2 (en) 2000-06-15 2003-11-26 Board of Regents, The University of Texas System Regulatable, catalytically active nucleic acids
EP2385067A1 (en) 2000-07-11 2011-11-09 Research Corporation Technologies, Inc. Artificial antibody polypeptides
EP1356075A4 (en) 2000-10-16 2005-04-13 Compound Therapeutics Inc PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS
US7598352B2 (en) 2000-11-17 2009-10-06 University Of Rochester Method of identifying polypeptide monobodies which bind to target proteins and use thereof
EP1572718A4 (en) 2001-04-04 2006-03-15 Univ Rochester BINDING POLYPEPTIDE MONOCORPS WITH INTEGRIN ALPHA NU BETA3 AND USE THEREOF
DK1390535T3 (da) 2001-04-26 2010-12-06 Amgen Mountain View Inc Kombinatoriske biblioteker af monomer-domæner
WO2003022858A2 (de) 2001-09-11 2003-03-20 Nascacell Gmbh Verfahren zum screenen von inhibitoren für die protein-protein-wechselwirkung sowie ribozyme hierzu
US20080193445A1 (en) 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
AU2003286624B2 (en) 2002-10-23 2008-11-13 Bristol-Myers Squibb Company Methods for treating viral infection using IL-28 and IL-29
US20080220049A1 (en) 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
KR20060129246A (ko) 2003-12-05 2006-12-15 컴파운드 쎄라퓨틱스, 인크. 타입 2 혈관 내피 성장 인자 수용체의 억제제
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1931770A4 (en) 2005-10-07 2009-11-25 Univ California NUCLEIC ACIDS CODING FOR MODIFIED CYTOCHROM P450 ENZYME AND METHOD OF USE THEREOF
JP5261187B2 (ja) 2005-11-23 2013-08-14 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａアンタゴニストおよび骨成長を促進するための使用
EA014531B1 (ru) 2006-02-24 2010-12-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Антиамилоидные иммуногенные композиции, способы и применения
JP2009534331A (ja) 2006-04-21 2009-09-24 トランジェーヌ、ソシエテ、アノニム Ｈｐｖ‐１８を主体とするパピローマウイルスワクチン
WO2008031098A1 (en) 2006-09-09 2008-03-13 The University Of Chicago Binary amino acid libraries for fibronectin type iii polypeptide monobodies
EP2076614A4 (en) 2006-10-16 2012-07-04 Univ Arizona SYNTHETIC ANTIBODIES
CA2670471A1 (en) * 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
ATE516814T1 (de) 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
EP2129397B1 (en) 2007-03-02 2018-10-31 Amgen, Inc. Methods and compositions for treating tumor diseases
US20090176654A1 (en) 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US20100285000A1 (en) 2007-08-20 2010-11-11 Bristol-Myers Squibb Company Use of vegfr-2 inhibitors for treating metastatic cancer
US8633297B2 (en) 2007-10-31 2014-01-21 Medimmune, Llc Protein scaffolds
WO2009073115A1 (en) 2007-11-28 2009-06-11 Bristol-Myers Squibb Company Combination vegfr2 therapy with mtor inhibitors
JP2011507529A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド Ｍ１３ファージのｐＩＸへの融合を介する代替の足場タンパク質融合ファージ提示
EP2234646A2 (en) 2007-12-27 2010-10-06 Novartis AG Improved fibronectin-based binding molecules and their use
CA2715312C (en) 2008-02-12 2012-02-07 Steven E. Nielsen Searchable electronic records of underground facility locate marking operations
KR20100128291A (ko) 2008-02-14 2010-12-07 브리스톨-마이어스 스큅 컴퍼니 Ｅｇｆｒ에 결합하는 조작된 단백질을 기초로 하는 표적화된 치료제
BRPI0913007A2 (pt) 2008-05-02 2019-09-24 Novartis Ag moléculas de ligação aprimoradas à base de fibronectina e usos das mesmas
EP2799448A1 (en) 2008-05-22 2014-11-05 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
ES2705714T3 (es) 2008-10-31 2019-03-26 Janssen Biotech Inc Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
JP5985826B2 (ja) 2008-12-16 2016-09-06 ノバルティス アーゲー 酵母ディスプレイ系
US20100210511A1 (en) 2009-02-11 2010-08-19 Bristol-Myers Squibb Company Combination VEGFR2 Therapy with Temozolomide
DK2396011T3 (en) 2009-02-12 2016-04-25 Janssen Biotech Inc Fibronectin TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, METHODS AND USES
US8067201B2 (en) 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
EP2464663A4 (en) 2009-08-13 2013-05-29 Massachusetts Inst Technology RECOMBINANT PROTEINS COMPRISING MUTANT DOMAINS OF FIBRONECTIN
WO2011051333A1 (en) 2009-10-30 2011-05-05 Novartis Ag Universal fibronectin type iii bottom-side binding domain libraries
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
US20110123545A1 (en) 2009-11-24 2011-05-26 Bristol-Myers Squibb Company Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
EP2533807A2 (en) 2010-02-12 2012-12-19 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
MX2012009050A (es) 2010-02-18 2012-09-07 Squibb Bristol Myers Co Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23).
US9249508B2 (en) 2010-03-14 2016-02-02 Mark S. Braiman Bromine-sensitized solar photolysis of carbon dioxide
SG184185A1 (en) 2010-04-13 2012-10-30 Medimmune Llc Trail r2-specific multimeric scaffolds
SG184220A1 (en) 2010-04-13 2012-11-29 Bristol Myers Squibb Co Fibronectin based scaffold domain proteins that bind pcsk9
HUE029622T2 (en) 2010-04-30 2017-03-28 Janssen Biotech Inc Stabilized fibronectin preparations, processes and applications
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
ES2573108T3 (es) 2010-05-26 2016-06-06 Bristol-Myers Squibb Company Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada
AU2011283646B2 (en) 2010-07-30 2015-07-09 Novartis Ag Fibronectin cradle molecules and libraries thereof
EP2655411A1 (en) 2010-12-22 2013-10-30 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind il-23
EP3144320B9 (en) 2011-04-13 2018-08-22 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
US9347058B2 (en) 2011-05-17 2016-05-24 Bristol-Myers Squibb Company Methods for the selection of binding proteins
EP2709669A1 (en) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
MX358827B (es) 2011-09-27 2018-09-05 Janssen Biotech Inc Supercóntigos de proteína basados en repeticiones de fibronectina tipo iii con superficies de unión alternativas.
CN113150117A (zh) 2014-03-20 2021-07-23 百时美施贵宝公司 新的结合血清白蛋白的纤连蛋白iii型结构域
EP3708580B1 (en) * 2015-09-23 2023-11-01 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains

Also Published As

Publication number Publication date
BR112012028162A2 (pt) 2020-10-13
US20190203248A1 (en) 2019-07-04
CA2798510A1 (en) 2011-11-10
US20150152147A1 (en) 2015-06-04
TW201138808A (en) 2011-11-16
CN107698682A (zh) 2018-02-16
US10221438B2 (en) 2019-03-05
WO2011140086A2 (en) 2011-11-10
CL2012003077A1 (es) 2013-03-22
CO6630173A2 (es) 2013-03-01
PE20130593A1 (es) 2013-05-12
JP6219357B2 (ja) 2017-10-25
AR081459A1 (es) 2012-09-05
TN2012000518A1 (en) 2014-04-01
US10934572B2 (en) 2021-03-02
US9540424B2 (en) 2017-01-10
MX2012012800A (es) 2012-12-17
CN103003301B (zh) 2016-09-21
EA201270775A1 (ru) 2013-07-30
JP2013531477A (ja) 2013-08-08
KR101854931B1 (ko) 2018-05-04
US20170145464A1 (en) 2017-05-25
EP2566888A2 (en) 2013-03-13
CN103003301A (zh) 2013-03-27
SG185091A1 (en) 2012-12-28
JP5876872B2 (ja) 2016-03-02
AU2011248273A1 (en) 2012-12-20
JP2018057368A (ja) 2018-04-12
SG10201503366XA (en) 2015-06-29
US20110305663A1 (en) 2011-12-15
WO2011140086A9 (en) 2011-12-29
IL222832A0 (en) 2012-12-31
EA029334B1 (ru) 2018-03-30
US8969289B2 (en) 2015-03-03
ZA201209091B (en) 2015-07-29
KR20130097083A (ko) 2013-09-02
JP2016106074A (ja) 2016-06-16
MX346557B (es) 2017-03-24
AU2011248273B2 (en) 2015-09-10
WO2011140086A3 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
UY33366A (es) FIBRONECTINA TIPO III A LA DÉCIMA (10Fn3) DE UNIÓN A SEROALBÚMINA Y MOLÉCULAS DE FUSIÓN QUE LAS COMPRENDE
DOP2014000083A (es) Inmunoenlazadores dirigidos contra el tnf
CO6382161A2 (es) Moleculas biespecificas de union a egfr/igfir
BR112016020175A2 (pt) domínios de fibronectina tipo iii de ligação à albumina sérica
AR114031A2 (es) Moléculas de unión a 4-1bb
ECSP14001260A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas
UY33319A (es) PROTEÍNAS QUE SE UNEN AL TNF-a
UY31123A1 (es) Proteinas de fusion natriureticas
CL2013003090A1 (es) Polipeptido que comprende una primera secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17f, il17-a/f, pero no a il-17a, y una segunda secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17a, il-17f y il17-a/f; composicion farmaceutica que lo comprende; y su uso.
WO2017053619A8 (en) Glypican-3binding fibronectin based scafflold molecules
UY35484A (es) Molécula de unión de cadena simple que comprenden ABP de extremo N
EA201491524A1 (ru) Связывающиеся с эритроцитами терапевтические средства
CO6680656A2 (es) Anticuerpos para metaloproteinasa -9 de matriz
CL2011002129A1 (es) Proteinas de union a il-17; construccion de proteina de union a il-17 que comprende un polipeptido ligador o un dominio constante de una inmunoglobulina; conjugado de proteina de union a il-17; vector y celula huesped; composicion para la liberacion de una proteina de union; metodo para reducir la actividad de la il-17.
BR112013013043A2 (pt) proteínas de repetição concebidas que se ligam á albumina sérica
CO7250445A2 (es) Proteínas de unión a antígeno st2
UY30324A1 (es) Proteinas de fusion del rage, formulaciones y métodos de uso
EA201390923A1 (ru) Модифицированное антитело с улучшенным полупериодом существования
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
BR112012013876A2 (pt) proteínas de ligação do antígeno humano que ligam o seu b-klotho, receptores de fgf e seus complexos
CL2012002884A1 (es) Polipeptido que comprende un dominio decimo de fibronectina de tipo iii que se unen a la proteina covertasa subtilisina kexina tipo q ( pcsk9); composicion farmacéutica que comprende dicho polipeptido.
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met
BR112013027224A2 (pt) proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados
AR080914A1 (es) Proteinas de union al beta-amiloide
EA201892796A1 (ru) Связывающиеся с сывороточным альбумином домены фибронектина типа iii

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200626